David Ruhl

David Ruhl is a seasoned neuroscientist currently serving as Principal Scientist and Translational Scientist at Neurocrine Biosciences since September 2020, leading multiple early-stage drug development programs involving small molecules and AAV-based gene therapy. Ruhl's expertise includes in vivo and in vitro pharmacology, as demonstrated by the development of a preclinical electrophysiology lab to evaluate late-stage compounds. Previously, Ruhl held roles such as Venture Fellow and Postdoctoral Scientist, focusing on neural coding of odor stimuli and neuroimaging data analysis. Ruhl's research background spans multiple institutions, including The Mind Research Network and the University of New Mexico, where clinical assessments and electrophysiological data collection were integral. Ruhl earned a PhD in Neuroscience from the University of Wisconsin-Madison and holds dual Bachelor's degrees in Psychology and Philosophy from The University of New Mexico.